ESC 2026 Hot Line Recap: 3 Trials Every Pharmacist Needs

In this episode of The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, recaps 3 Hot Line trials from the European Society of Cardiology (ESC) Congress 2026 and their implications for pharmacists. The phase 3 CARDIO-TTRansform trial (NCT04136171) tested eplontersen (Wainua; Ionis Pharmaceuticals, AstraZeneca) in transthyretin amyloid cardiomyopathy and missed its primary end point (rate ratio, 0.89), although a prespecified subgroup not on background TTR stabilizers showed nominal benefit—a reminder that lowering a biomarker does not guarantee clinical efficacy and that background therapy shapes trial results. The phase 4 SINGLE-AF trial (NCT04437654) found that direct oral anticoagulation reduced the primary composite end point by 69% in patients with atrial fibrillation at intermediate stroke risk, without increasing the risk of major bleeding, although absolute event rates were low. POETII (NCT03851575) showed that a response-tailored, shorter antibiotic course was noninferior for selected patients with left-sided infective endocarditis, cutting median therapy from 41 to 26 days but carrying a higher relapse signal.

Beavers stressed that pharmacists should weigh incremental benefit, absolute vs relative risk, longitudinal risk surveillance, antimicrobial stewardship, and the monitoring infrastructure new therapies demand, concluding that health-system implementation matters as much as efficacy.